Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

被引:75
作者
Boulay, Denis [1 ]
Pichat, Philippe [1 ]
Dargazanli, Gihad [1 ]
Estenne-Bouhtou, Genevieve [1 ]
Terranova, Jean Paul [2 ]
Rogacki, Nancy [3 ]
Stemmelin, Jeanne [1 ]
Coste, Annick [1 ]
Lanneau, Christophe [1 ]
Desvignes, Christophe [2 ]
Cohen, Caroline [1 ]
Alonso, Richard [2 ]
Vige, Xavier [1 ]
Biton, Bruno [1 ]
Steinberg, Regis [2 ]
Sevrin, Mireille [1 ]
Oury-Donat, Florence [2 ]
George, Pascal [1 ]
Bergis, Olivier [1 ]
Griebel, Guy [1 ]
Avenet, Patrick [1 ]
Scatton, Bernard [1 ]
机构
[1] Sanofi Aventis, CNS Dept, F-92220 Bagneux, France
[2] Sanofi Aventis, Montpellier, France
[3] Sanofi Aventis, Bridgewater, NJ USA
关键词
atypical antipsychotic; antidepressant; glycine; GlyT1; inhibitor; schizophrenia; SSR103800;
D O I
10.1016/j.pbb.2008.06.009
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
On native human, rat and mouse glycine transporter-1 (GlyT1), SSR130800 behaves as a selective inhibitor with IC50 values of 1.9, 5.3 and 6.8 nM respectively. It reversibly blocked glycine uptake in mouse brain cortical homogenates, increased extracellular levels of glycine in the rat prefrontal cortex, and potentiated NMDA-mediated excitatory postsynaptic currents in rat hippocampal slices. SSR103800 (30 mg/kg, p.o.) decreased MK-801- and PCP-induced locomotor hyperactivity in rodents. SSR103800 (1 and 10 mg/kg, p.o.) attenuated social recognition deficit in adult rats induced by neonatal injections of PCP (10 mg/kg, s.c., on post-natal day 7, 9 and 11). SSR103800 (3 mg/kg, p.o.) counteracted the deficit in short-term visual episodic-like memory induced by a low challenge dose of PCP (1 mg/kg, i.p.), in PCP-sensitized rats (10 mg/kg, i.p.). SSR103800 (30 mg/kg, i.p.) increased the prepulse inhibition of the startle reflex in DBA/1J mice. SSR103800 decreased defensive- and despair-related behaviors in the tonic immobility test in gerbils (10 and 30 mg/kg, p.o.) and in the forced-swimming procedure in rats (1 and 3 mg/kg, p.o.), respectively. These findings suggest that SSR103800 may have a therapeutic potential in the management of the core symptoms of schizophrenia and comorbid depression states. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:47 / 58
页数:12
相关论文
共 44 条
[1]   Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression [J].
Altamura, C ;
Maes, M ;
Dai, J ;
Meltzer, HY .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1995, 5 :71-75
[2]   Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine [J].
Andersen, JD ;
Pouzet, B .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (06) :1080-1090
[3]  
[Anonymous], RAT BRAIN STEREOTAXI
[4]  
BERT I, 1996, CHROMATOGR A, V755, P99
[5]   Discovery and SAR of Org 24598 - A selective glycine uptake inhibitor [J].
Brown, A ;
Carlyle, I ;
Clark, J ;
Hamilton, W ;
Gibson, S ;
McGarry, G ;
McEachen, S ;
Rae, D ;
Thorn, S ;
Walker, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (15) :2007-2009
[6]   Neurocircuitries and neurotransmitter interactions in schizophrenia [J].
Carlsson, A .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :21-28
[7]   Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment [J].
Cryan, JF ;
Page, ME ;
Lucki, I .
PSYCHOPHARMACOLOGY, 2005, 182 (03) :335-344
[8]   Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain [J].
Cubelos, B ;
Giménez, C ;
Zafra, F .
CEREBRAL CORTEX, 2005, 15 (04) :448-459
[9]   Functional mechanisms of episodic memory impairment in schizophrenia [J].
Danion, Jean-Marie ;
Huron, Caroline ;
Vidailhet, Pierre ;
Berna, Fabrice .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2007, 52 (11) :693-701
[10]   Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-I SSR504734, a potential new type of antipsychotic [J].
Depoortère, R ;
Dargazanli, G ;
Estenne-Bouhtou, G ;
Coste, A ;
Lanneau, C ;
Desvignes, C ;
Poncelet, M ;
Heaulme, M ;
Santucci, V ;
Decobert, M ;
Cudennec, A ;
Voltz, C ;
Boulay, D ;
Terranova, JP ;
Stemmelin, J ;
Roger, P ;
Marabout, B ;
Sevrin, M ;
Vigé, X ;
Biton, B ;
Steinberg, R ;
Françon, D ;
Alonso, R ;
Avenet, P ;
Oury-Donat, F ;
Perrault, G ;
Griebel, G ;
George, P ;
Soubrié, P ;
Scatton, B .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (11) :1963-1985